Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel (1S,3R)-RSL3-Encapsulated Polyunsaturated Fatty Acid Rich Liposomes Sensitise Multiple Myeloma Cells to Ferroptosis-Mediated Cell Death.

International journal of molecular sciences·2025
Same author

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.

International journal of molecular sciences·2023
Same author

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.

Blood·2022
Same author

Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.

ACS pharmacology & translational science·2021
Same author

A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.

British journal of haematology·2021
Same author

Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.

ACS pharmacology & translational science·2021
Same journal

Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities.

Journal of hematology & oncology·2026
Same journal

Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting.

Journal of hematology & oncology·2026
Same journal

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.

Journal of hematology & oncology·2026
Same journal

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Journal of hematology & oncology·2026
Same journal

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same journal

Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density.

Journal of hematology & oncology·2026
See all related articles

Related Experiment Video

Updated: Oct 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Prognostic and predictive biomarker developments in multiple myeloma.

Craig T Wallington-Beddoe1,2,3,4, Rachel L Mynott5

  • 1College of Medicine and Public Health, Level 4, Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, SA, 5042, Australia. craig.wallingtonbeddoe@flinders.edu.au.

Journal of Hematology & Oncology
|September 24, 2021
PubMed
Summary
This summary is machine-generated.

New biomarkers are crucial for personalized multiple myeloma treatment. This review explores diagnostic, prognostic, and predictive biomarkers to guide individualized patient care and novel therapies.

Keywords:
BiomarkerDiagnosisMultiple myelomaPrognosisTherapy

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Related Experiment Videos

Last Updated: Oct 19, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Area of Science:

  • Hematology
  • Oncology
  • Biomarker Research

Background:

  • Current multiple myeloma management lacks individualized risk stratification.
  • Existing biomarkers offer prognostic information but are insufficient for treatment modification or prediction.
  • Novel therapies necessitate clinically relevant biomarkers for personalized treatment strategies.

Purpose of the Study:

  • To review current biomarker categories in multiple myeloma.
  • To discuss the application of biomarkers in diagnosis, prognosis, and prediction.
  • To highlight the need for advanced biomarkers in the era of novel therapies.

Main Methods:

  • Literature review of multiple myeloma biomarker research.
  • Analysis of diagnostic, prognostic, and predictive biomarker applications.
  • Discussion of emerging technologies and tumor biology in biomarker development.

Main Results:

  • Identified key biomarker categories relevant to multiple myeloma.
  • Detailed the utility of biomarkers for patient stratification.
  • Emphasized the gap in utilizing biomarkers for predictive treatment decisions.

Conclusions:

  • Biomarker development is essential for advancing personalized medicine in multiple myeloma.
  • Future research should focus on integrating biomarkers into treatment algorithms.
  • Individualized patient management is the ultimate goal, driven by robust biomarker data.